Breast Cancer

Bone loss is a natural part of aging — especially due to menopause for women — but certain cancer treatments and prolonged cancer survival can increase the risk for bone loss and the related outcome of fractures.

Trastuzumab deruxtecan reduced risk for disease progression or death compared with trastuzumab emtansine among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.

Women diagnosed with breast or gynecologic cancers underutilized both assisted reproductive technology and fertility-sparing oncology care, according to study results.

Adjuvant olaparib significantly extended OS among patients with HER2-negative high-risk early-stage breast cancer and germline BRCA1/BRCA2 mutations, according to results of the randomized phase 3 OlympiA study.

Cancer screening remains in need of urgent attention, and online resources may help facilities close gaps and address screenings missed in 2020, according to a prospective quality improvement study published in Cancer.

In this video, Kevin Kalinsky, MD, discussed the approval of single agent pembrolizumab, which is agnostic to tumor histology the role of ARP inhibitors for patients with BRCA mutations.

In this video, Kevin Kalinsky, MD, discussed recent developments in the treatment of metastatic triple-negative breast cancer presented at 39th Miami Breast Cancer Conference.

In this video, Kevin Kalinsky, MD, an associate professor of medicine at New York-Presbyterian Hospital/Columbia University Medical Center, discussed the Destiny 04 Trial presented at 39th Miami Breast Cancer Conference.

In this video, Kevin Kalinsky, MD, discussed new data on antibody-drug conjugates, including sacituzumab, presented at 39th Miami Breast Cancer Conference.

Among survivors of nine common cancers, risk for CV death overtook cancer mortality for most cancer subtypes among patients aged at least 80 years, researchers reported.